Extended Data Fig. 6: Characterization of Lysine 48 mutants of GPX4 in silico.
From: Characterization of a patient-derived variant of GPX4 for precision therapy
a, In silico docking of GSH to GPX4U46C, GPX4K48A, or GPX4K48L. Top covalent-docking pose of GSH on GPX4U46C (top left). 2D Ligand interaction diagram of GSH with GPX4U46C, GPX4K48A, or GPX4K48L in their individually top covalent-docking pose (top right and bottom panels). b, HT1080 overexpressing exogenous WT, K48A, or K48L GFP-GPX4 and a control line were tested for IKE sensitivity. Data are plotted as means ± SD of three biologically independent replicate experiments.
